Sinphar Pharmaceutical Co Ltd (1734) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) has a cash flow conversion efficiency ratio of 0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$116.42 Million ≈ $3.67 Million USD) by net assets (NT$3.81 Billion ≈ $119.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sinphar Pharmaceutical Co Ltd (1734) balance sheet quality index to measure how much of total assets are equity-financed.
Sinphar Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Sinphar Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 1734 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Sinphar Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinphar Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asia Electronic Material Co Ltd
TWO:4939
|
0.055x |
|
Smart Sand Inc
NASDAQ:SND
|
0.013x |
|
Creotech Quantum SA
WAR:CRQ
|
N/A |
|
Taigen Biopharmaceuticals Holdings Ltd
TWO:4157
|
0.043x |
|
Xplora Technologies As
OL:XPLRA
|
0.295x |
|
Platinum Group Metals Ltd
TO:PTM
|
-0.014x |
|
Hup Seng Industries Bhd
KLSE:5024
|
0.135x |
|
ÜSTRA Hannoversche Verkehrsbetriebe Aktiengesellschaft
F:HVB
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Sinphar Pharmaceutical Co Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Sinphar Pharmaceutical Co Ltd from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Sinphar Pharmaceutical Co Ltd (1734) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.72 Billion ≈ $117.05 Million |
NT$584.66 Million ≈ $18.42 Million |
0.157x | -5.97% |
| 2024-12-31 | NT$3.55 Billion ≈ $111.72 Million |
NT$593.51 Million ≈ $18.70 Million |
0.167x | +91.89% |
| 2023-12-31 | NT$3.40 Billion ≈ $107.05 Million |
NT$296.37 Million ≈ $9.34 Million |
0.087x | -34.03% |
| 2022-12-31 | NT$3.22 Billion ≈ $101.35 Million |
NT$425.30 Million ≈ $13.40 Million |
0.132x | +200.15% |
| 2021-12-31 | NT$3.08 Billion ≈ $96.95 Million |
NT$135.54 Million ≈ $4.27 Million |
0.044x | -5.41% |
| 2020-12-31 | NT$3.14 Billion ≈ $99.05 Million |
NT$146.39 Million ≈ $4.61 Million |
0.047x | +287.63% |
| 2019-12-31 | NT$3.20 Billion ≈ $100.91 Million |
NT$-79.49 Million ≈ $-2.50 Million |
-0.025x | -206.85% |
| 2018-12-31 | NT$3.42 Billion ≈ $107.84 Million |
NT$79.50 Million ≈ $2.50 Million |
0.023x | -61.69% |
| 2017-12-31 | NT$3.63 Billion ≈ $114.26 Million |
NT$219.87 Million ≈ $6.93 Million |
0.061x | +162.99% |
| 2016-12-31 | NT$3.78 Billion ≈ $119.16 Million |
NT$87.18 Million ≈ $2.75 Million |
0.023x | -67.46% |
| 2015-12-31 | NT$3.96 Billion ≈ $124.77 Million |
NT$280.53 Million ≈ $8.84 Million |
0.071x | +94.44% |
| 2014-12-31 | NT$4.08 Billion ≈ $128.50 Million |
NT$148.58 Million ≈ $4.68 Million |
0.036x | -57.16% |
| 2013-12-31 | NT$3.49 Billion ≈ $110.08 Million |
NT$297.09 Million ≈ $9.36 Million |
0.085x | +39.12% |
| 2012-12-31 | NT$2.69 Billion ≈ $84.77 Million |
NT$164.45 Million ≈ $5.18 Million |
0.061x | -27.91% |
| 2011-12-31 | NT$2.66 Billion ≈ $83.82 Million |
NT$225.58 Million ≈ $7.11 Million |
0.085x | -29.94% |
| 2010-12-31 | NT$2.16 Billion ≈ $68.08 Million |
NT$261.49 Million ≈ $8.24 Million |
0.121x | -18.26% |
| 2009-12-31 | NT$2.09 Billion ≈ $65.96 Million |
NT$309.94 Million ≈ $9.76 Million |
0.148x | -3.04% |
| 2008-12-31 | NT$1.77 Billion ≈ $55.92 Million |
NT$271.01 Million ≈ $8.54 Million |
0.153x | +48.45% |
| 2007-12-31 | NT$1.70 Billion ≈ $53.56 Million |
NT$174.85 Million ≈ $5.51 Million |
0.103x | +2.74% |
| 2006-12-31 | NT$1.66 Billion ≈ $52.42 Million |
NT$166.57 Million ≈ $5.25 Million |
0.100x | +34.84% |
| 2005-12-31 | NT$1.64 Billion ≈ $51.81 Million |
NT$122.09 Million ≈ $3.85 Million |
0.074x | -44.09% |
| 2004-12-31 | NT$1.32 Billion ≈ $41.47 Million |
NT$174.81 Million ≈ $5.51 Million |
0.133x | +3.62% |
| 2003-12-31 | NT$942.90 Million ≈ $29.71 Million |
NT$120.84 Million ≈ $3.81 Million |
0.128x | -- |
About Sinphar Pharmaceutical Co Ltd
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, in… Read more